---
document_datetime: 2025-12-29 14:34:35
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nimvastid.html
document_name: nimvastid.html
version: success
processing_time: 0.1407359
conversion_datetime: 2025-12-30 09:09:05.549947
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nimvastid

[RSS](/en/individual-human-medicine.xml/66426)

##### Authorised

This medicine is authorised for use in the European Union

rivastigmine Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Nimvastid](#more-information-on-nimvastid-1314)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78076)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).

Expand section

Collapse section

## What is Nimvastid?

Nimvastid is a medicine that contains the active substance rivastigmine. It is available as capsules (yellow: 1.5 mg, orange: 3 mg, brownish red: 4.5 mg, and brownish red and orange: 6 mg) and as white orodispersible tablets (1.5 mg, 3 mg, 4.5 mg, and 6 mg). Orodispersible means that the tablets dissolve in the mouth.

Nimvastid is a 'generic medicine'. This means that Nimvastid is similar to a 'reference medicine' already authorised in the European Union (EU) called Exelon.

## What is Nimvastid used for?

Nimvastid is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.

It is also used to treat mild to moderately severe dementia in patients with Parkinson's disease.

The medicine can only be obtained with a prescription.

## How is Nimvastid used?

Treatment with Nimvastid should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease. Treatment should only be started if a caregiver is available who will regularly monitor the use of Nimvastid by the patient. Treatment should continue as long as the medicine has a benefit, but the dose can be reduced or treatment interrupted if the patient has side effects.

Nimvastid should be given twice a day, with morning and evening meals. The capsules should be swallowed whole. Nimvastid orodispersible tablets should be placed on the tongue, where they disintegrate quickly in the saliva before being swallowed.

The starting dose for Nimvastid is 1.5 mg twice a day. In patients who tolerate this dose, it can be increased in 1.5-mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day. The highest tolerated dose should be used to get the maximum benefit, but the dose should not exceed 6 mg twice a day.

## How does Nimvastid work?

The active substance in Nimvastid, rivastigmine, is an antidementia medicine. In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a chemical that allows nerve cells to communicate with each other). Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Nimvastid allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease.

## How has Nimvastid been studied?

Because Nimvastid is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (this means that the two medicines produce the same levels of the active substance in the body).

## What are the benefit and risk of Nimvastid?

Because Nimvastid is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.

## Why has Nimvastid been approved?

The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Nimvastid has been shown to have comparable quality and to be bioequivalent to Exelon. Therefore, the CHMP's view was that, as for Exelon, the benefit outweighs the identified risk. The Committee recommended that Nimvastid be given marketing authorisation.

## Other information about Nimvastid

The European Commission granted a marketing authorisation valid throughout the European Union for Nimvastid to KRKA,d.d., Novo mesto on 11 May 2009.

Nimvastid : EPAR - Summary for the public

English (EN) (42.81 KB - PDF)

**First published:** 04/06/2009

**Last updated:** 04/06/2009

[View](/en/documents/overview/nimvastid-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-569)

български (BG) (229.49 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/bg/documents/overview/nimvastid-epar-summary-public_bg.pdf)

español (ES) (104.19 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/es/documents/overview/nimvastid-epar-summary-public_es.pdf)

čeština (CS) (219.19 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/cs/documents/overview/nimvastid-epar-summary-public_cs.pdf)

dansk (DA) (103.77 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/da/documents/overview/nimvastid-epar-summary-public_da.pdf)

Deutsch (DE) (104.68 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/de/documents/overview/nimvastid-epar-summary-public_de.pdf)

eesti keel (ET) (103.52 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/et/documents/overview/nimvastid-epar-summary-public_et.pdf)

ελληνικά (EL) (224.35 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/el/documents/overview/nimvastid-epar-summary-public_el.pdf)

français (FR) (104.46 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/fr/documents/overview/nimvastid-epar-summary-public_fr.pdf)

italiano (IT) (103.97 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/it/documents/overview/nimvastid-epar-summary-public_it.pdf)

latviešu valoda (LV) (220.74 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/lv/documents/overview/nimvastid-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (215.21 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/lt/documents/overview/nimvastid-epar-summary-public_lt.pdf)

magyar (HU) (210.32 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/hu/documents/overview/nimvastid-epar-summary-public_hu.pdf)

Malti (MT) (221.04 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/mt/documents/overview/nimvastid-epar-summary-public_mt.pdf)

Nederlands (NL) (103.89 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/nl/documents/overview/nimvastid-epar-summary-public_nl.pdf)

polski (PL) (226.65 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/pl/documents/overview/nimvastid-epar-summary-public_pl.pdf)

português (PT) (104.72 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/pt/documents/overview/nimvastid-epar-summary-public_pt.pdf)

română (RO) (210.76 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/ro/documents/overview/nimvastid-epar-summary-public_ro.pdf)

slovenčina (SK) (214.17 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/sk/documents/overview/nimvastid-epar-summary-public_sk.pdf)

slovenščina (SL) (206.32 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/sl/documents/overview/nimvastid-epar-summary-public_sl.pdf)

Suomi (FI) (104.1 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/fi/documents/overview/nimvastid-epar-summary-public_fi.pdf)

svenska (SV) (103.61 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

04/06/2009

[View](/sv/documents/overview/nimvastid-epar-summary-public_sv.pdf)

## Product information

Nimvastid : EPAR - Product Information

English (EN) (366.09 KB - PDF)

**First published:** 04/06/2009

**Last updated:** 17/07/2025

[View](/en/documents/product-information/nimvastid-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-438)

български (BG) (410.29 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/bg/documents/product-information/nimvastid-epar-product-information_bg.pdf)

español (ES) (385.55 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/es/documents/product-information/nimvastid-epar-product-information_es.pdf)

čeština (CS) (361.34 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/cs/documents/product-information/nimvastid-epar-product-information_cs.pdf)

dansk (DA) (374.48 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/da/documents/product-information/nimvastid-epar-product-information_da.pdf)

Deutsch (DE) (401.2 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/de/documents/product-information/nimvastid-epar-product-information_de.pdf)

eesti keel (ET) (371.58 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/et/documents/product-information/nimvastid-epar-product-information_et.pdf)

ελληνικά (EL) (413.94 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/el/documents/product-information/nimvastid-epar-product-information_el.pdf)

français (FR) (384.59 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/fr/documents/product-information/nimvastid-epar-product-information_fr.pdf)

hrvatski (HR) (371.07 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/hr/documents/product-information/nimvastid-epar-product-information_hr.pdf)

íslenska (IS) (371.54 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/is/documents/product-information/nimvastid-epar-product-information_is.pdf)

italiano (IT) (392.62 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/it/documents/product-information/nimvastid-epar-product-information_it.pdf)

latviešu valoda (LV) (380.45 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/lv/documents/product-information/nimvastid-epar-product-information_lv.pdf)

lietuvių kalba (LT) (384.37 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/lt/documents/product-information/nimvastid-epar-product-information_lt.pdf)

magyar (HU) (405.19 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/hu/documents/product-information/nimvastid-epar-product-information_hu.pdf)

Malti (MT) (448.22 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/mt/documents/product-information/nimvastid-epar-product-information_mt.pdf)

Nederlands (NL) (380.04 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/nl/documents/product-information/nimvastid-epar-product-information_nl.pdf)

norsk (NO) (368.77 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/no/documents/product-information/nimvastid-epar-product-information_no.pdf)

polski (PL) (380.74 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

21/11/2025

[View](/pl/documents/product-information/nimvastid-epar-product-information_pl.pdf)

português (PT) (385.56 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/pt/documents/product-information/nimvastid-epar-product-information_pt.pdf)

română (RO) (386.16 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/ro/documents/product-information/nimvastid-epar-product-information_ro.pdf)

slovenčina (SK) (384.91 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/sk/documents/product-information/nimvastid-epar-product-information_sk.pdf)

slovenščina (SL) (367.65 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/sl/documents/product-information/nimvastid-epar-product-information_sl.pdf)

Suomi (FI) (373.93 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/fi/documents/product-information/nimvastid-epar-product-information_fi.pdf)

svenska (SV) (363 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

17/07/2025

[View](/sv/documents/product-information/nimvastid-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000284684 15/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nimvastid : EPAR - All Authorised presentations

English (EN) (14.31 KB - PDF)

**First published:** 04/06/2009

**Last updated:** 16/07/2009

[View](/en/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-259)

български (BG) (88.04 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/bg/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.14 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/es/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_es.pdf)

čeština (CS) (86.21 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/cs/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (13.09 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/da/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.09 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/de/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.71 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/et/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (94.42 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/el/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_el.pdf)

français (FR) (45.85 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/fr/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (47.64 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/it/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (122.31 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/lv/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (117.89 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/lt/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (115.32 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/hu/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (116.93 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/mt/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (47.07 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/nl/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_nl.pdf)

polski (PL) (120.67 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/pl/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.31 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/pt/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_pt.pdf)

română (RO) (114.3 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/ro/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (116.76 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/sk/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (83.88 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/sl/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.77 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/fi/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (47.42 KB - PDF)

**First published:**

04/06/2009

**Last updated:**

16/07/2009

[View](/sv/documents/all-authorised-presentations/nimvastid-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nimvastid Active substance rivastigmine International non-proprietary name (INN) or common name rivastigmine Therapeutic area (MeSH)

- Dementia
- Alzheimer Disease
- Parkinson Disease

Anatomical therapeutic chemical (ATC) code N06DA03

### Pharmacotherapeutic group

Psychoanaleptics

### Therapeutic indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

## Authorisation details

EMA product number EMEA/H/C/001029

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Krka, d.d., Novo mesto

Šmarješka cesta 6

Marketing authorisation issued 11/05/2009 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nimvastid : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (305.17 KB - PDF)

**First published:** 26/03/2025

**Last updated:** 17/07/2025

[View](/en/documents/procedural-steps-after/nimvastid-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Nimvastid : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (131.18 KB - PDF)

**First published:** 16/07/2010

**Last updated:** 10/01/2024

[View](/en/documents/procedural-steps-after/nimvastid-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Nimvastid : EPAR - Public assessment report

English (EN) (313.85 KB - PDF)

**First published:** 04/06/2009

**Last updated:** 04/06/2009

[View](/en/documents/assessment-report/nimvastid-epar-public-assessment-report_en.pdf)

#### More information on Nimvastid

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Nimvastid : EPAR - Product information - tracked changes

English (EN) (155.39 KB - DOCX)

**First published:** 17/07/2025

[View](/en/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_en.docx)

[Other languages (23)](#file-language-dropdown-349)

български (BG) (189.15 KB - DOCX)

**First published:**

17/07/2025

[View](/bg/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_bg.docx)

español (ES) (159.95 KB - DOCX)

**First published:**

17/07/2025

[View](/es/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_es.docx)

čeština (CS) (160.36 KB - DOCX)

**First published:**

17/07/2025

[View](/cs/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (162.45 KB - DOCX)

**First published:**

17/07/2025

[View](/da/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (172.26 KB - DOCX)

**First published:**

17/07/2025

[View](/de/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_de.docx)

ελληνικά (EL) (195.72 KB - DOCX)

**First published:**

17/07/2025

[View](/el/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_el.docx)

français (FR) (169.12 KB - DOCX)

**First published:**

17/07/2025

[View](/fr/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (157.5 KB - DOCX)

**First published:**

17/07/2025

[View](/hr/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (148.51 KB - DOCX)

**First published:**

17/07/2025

[View](/is/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_is.docx)

italiano (IT) (172.67 KB - DOCX)

**First published:**

17/07/2025

[View](/it/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (165.51 KB - DOCX)

**First published:**

17/07/2025

[View](/lv/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (169.19 KB - DOCX)

**First published:**

17/07/2025

[View](/lt/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (167.47 KB - DOCX)

**First published:**

17/07/2025

[View](/hu/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (168.3 KB - DOCX)

**First published:**

17/07/2025

[View](/mt/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (159.79 KB - DOCX)

**First published:**

17/07/2025

[View](/nl/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (150.39 KB - DOCX)

**First published:**

17/07/2025

[View](/no/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_no.docx)

polski (PL) (167.66 KB - DOCX)

**First published:**

17/07/2025

[View](/pl/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_pl.docx)

português (PT) (152.4 KB - DOCX)

**First published:**

17/07/2025

[View](/pt/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_pt.docx)

română (RO) (180.4 KB - DOCX)

**First published:**

17/07/2025

[View](/ro/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (164.32 KB - DOCX)

**First published:**

17/07/2025

[View](/sk/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (156.98 KB - DOCX)

**First published:**

17/07/2025

[View](/sl/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (161.17 KB - DOCX)

**First published:**

17/07/2025

[View](/fi/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (149.61 KB - DOCX)

**First published:**

17/07/2025

[View](/sv/documents/product-information-tracked-changes/nimvastid-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/07/2025

## Share this page

[Back to top](#main-content)